HOLON, Israel, April 11, 2018 /PRNewswire/ --
In its official opinion, the opposition divisionof the European Patent Office found the Turzi blood separation patent, which is licensed to Regenlab, to be invalid on the grounds of added matter, lack of novelty and lack of sufficient disclosure
In this preliminary opinion, the opposition division of the EPO found the Turzi patent to be invalid on the grounds of (i) added matter, (ii) lack of novelty, and (iii) lack of sufficient disclosure. With respect to the prior disclosure issue, the Opposition Division of the EPO found that "it is shown beyond any reasonable doubt that the product was available prior to priority, a prior use had taken place and the features of the product could be investigated."
The decision will be made after oral proceedings, now scheduled for November, 2018. The opinion is preliminary and non-binding.
"We are pleased and extremely encouraged by the EPO current view of the Turzi/Regenlab patent," stated Aaron Esteron, the CEO of Estar.
Unless the Opposition Division of the EPO changes its views very significantly at an oral hearing, the result will be the complete invalidation and revocation of Turzi and Regenlab main patent in all contracting states of the European Patent Convention.
About Estar Technologies Ltd. Founded in 1991, Estar is a global leader and innovator in the biologics and platelet rich plasma arena. Estar's products are globally marketed mainly under the renowned Tropocells® and Cellenis® brands. Estar has developed a unique and effective technology for the simple preparation of pure PRP by enabling the physician to easily and effectively separate and concentrate growth factors taken from the patient's own blood for the purpose of building new tissues and effectively accelerate the natural autologous wound healing process.
Additional information about Estar can be found at http://www.estar-medical.com.
Contact: Yuval Esteron email@example.com
SOURCE Estar Technologies Ltd. (Estar)
Subscribe to our Free Newsletters!
Lazy eye or amblyopia occurs when sight in one eye is less than the other in early childhood due to ...
Tracheal or windpipe cancer is a rare cancer and its cause is unclear. The most common squamous ...
Tecovirimat can be used to treat smallpox disease in adult and pediatric patients who weigh at ...View All